290 related articles for article (PubMed ID: 30891101)
1. HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.
Wang Y; Jiang Z; Yan J; Ying S
Dis Markers; 2019; 2019():4183157. PubMed ID: 30891101
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of fibulin-3 in tumor tissue predicts poor survival of malignant mesothelioma patients from hand-spinning asbestos exposed area in eastern China.
Jiang Z; Shen W; Ying S; Gao Z; He X; Chen R; Xia H; Guo X; Fang Y; Zhang Y; Miao J; Zhou J; Zhang X; Chen J; Lou J
Sci Rep; 2020 Nov; 10(1):20373. PubMed ID: 33230247
[TBL] [Abstract][Full Text] [Related]
3. HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma.
Pellegrini L; Xue J; Larson D; Pastorino S; Jube S; Forest KH; Saad-Jube ZS; Napolitano A; Pagano I; Negi VS; Bianchi ME; Morris P; Pass HI; Gaudino G; Carbone M; Yang H
Oncotarget; 2017 Apr; 8(14):22649-22661. PubMed ID: 28186988
[TBL] [Abstract][Full Text] [Related]
4. Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression.
Yang H; Pellegrini L; Napolitano A; Giorgi C; Jube S; Preti A; Jennings CJ; De Marchis F; Flores EG; Larson D; Pagano I; Tanji M; Powers A; Kanodia S; Gaudino G; Pastorino S; Pass HI; Pinton P; Bianchi ME; Carbone M
Cell Death Dis; 2015 Jun; 6(6):e1786. PubMed ID: 26068794
[TBL] [Abstract][Full Text] [Related]
5. The role of high-mobility group protein box 1 in lung cancer.
Wu XJ; Chen YY; Gong CC; Pei DS
J Cell Biochem; 2018 Aug; 119(8):6354-6365. PubMed ID: 29665052
[TBL] [Abstract][Full Text] [Related]
6. Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.
Ying S; Jiang Z; He X; Yu M; Chen R; Chen J; Ru G; Chen Y; Chen W; Zhu L; Li T; Zhang Y; Guo X; Yin X; Zhang X; Lou J
Dis Markers; 2017; 2017():5756102. PubMed ID: 28348451
[TBL] [Abstract][Full Text] [Related]
7. High mobility group box 1 mediates inflammatory responses in malignant peritoneal mesothelioma.
Wang L; Wang X; Sun N; Liu W
Int Immunopharmacol; 2024 May; 133():112039. PubMed ID: 38613884
[TBL] [Abstract][Full Text] [Related]
8. Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets.
Crispi S; Cardillo I; Spugnini EP; Citro G; Menegozzo S; Baldi A
Curr Cancer Drug Targets; 2010 Feb; 10(1):19-26. PubMed ID: 20088796
[TBL] [Abstract][Full Text] [Related]
9. Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma.
Rrapaj E; Trisolini E; Bertero L; Salvo M; Indellicato R; Andorno S; Garcia-Manteiga JM; Rena O; Boldorini RL
Histopathology; 2018 May; 72(6):1039-1050. PubMed ID: 29356044
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
[TBL] [Abstract][Full Text] [Related]
11. Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches-a narrative review.
Zolondick AA; Gaudino G; Xue J; Pass HI; Carbone M; Yang H
Precis Cancer Med; 2021 Sep; 4():. PubMed ID: 35098108
[TBL] [Abstract][Full Text] [Related]
12. Fibulin-3 as biomarker of malignant mesothelioma.
Ledda C; Caltabiano R; Vella F; Matera S; Marconi A; Loreto C; Rapisarda V
Biomark Med; 2019 Jul; 13(10):875-886. PubMed ID: 31237454
[TBL] [Abstract][Full Text] [Related]
13. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
14. EphB4: A promising target for upper aerodigestive malignancies.
Salgia R; Kulkarni P; Gill PS
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):128-137. PubMed ID: 29369779
[TBL] [Abstract][Full Text] [Related]
15. HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma.
Suarez JS; Novelli F; Goto K; Ehara M; Steele M; Kim JH; Zolondick AA; Xue J; Xu R; Saito M; Pastorino S; Minaai M; Takanishi Y; Emi M; Pagano I; Wakeham A; Berger T; Pass HI; Gaudino G; Mak TW; Carbone M; Yang H
Proc Natl Acad Sci U S A; 2023 Sep; 120(39):e2307999120. PubMed ID: 37729199
[TBL] [Abstract][Full Text] [Related]
16. The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer.
Feng A; Tu Z; Yin B
Oncotarget; 2016 Apr; 7(15):20507-19. PubMed ID: 26840258
[TBL] [Abstract][Full Text] [Related]
17. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma.
Jube S; Rivera ZS; Bianchi ME; Powers A; Wang E; Pagano I; Pass HI; Gaudino G; Carbone M; Yang H
Cancer Res; 2012 Jul; 72(13):3290-301. PubMed ID: 22552293
[TBL] [Abstract][Full Text] [Related]
18. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
[TBL] [Abstract][Full Text] [Related]
19. Malignant Mesothelioma: Time to Translate?
Napolitano A; Carbone M
Trends Cancer; 2016 Sep; 2(9):467-474. PubMed ID: 28603777
[TBL] [Abstract][Full Text] [Related]
20. Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma.
Carbone M; Minaai M; Takinishi Y; Pagano I; Yang H
J Transl Med; 2023 Oct; 21(1):749. PubMed ID: 37880686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
